Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Application (C.Difficle, Crohns Disease, IBS, Diabetes, Others), By Region (MEA, Asia Pacific), And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends
The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 358.07 million by 2030, expanding at a CAGR of 37.77 % from 2024 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.
The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.
Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.
Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology’s 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.
The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.
Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights
Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends
The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 358.07 million by 2030, expanding at a CAGR of 37.77 % from 2024 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.
The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.
Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.
Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology’s 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.
The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.
Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights
- C.difficle held the largest revenue share in 2023 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market
- Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion
- North America has dominated the market with the largest market share, primarily due to the presence of key players and increasing investments in research and development activities in this region. The growing demand for effective treatments for various diseases, such as C.difficile, Crohn's disease, and IBS, has also contributed to the market growth in North America.
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Live Biotherapeutic Products And Microbiome CDMO Market: Cagr Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
CHAPTER 3 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Live Biotherapeutic Products And Microbiome CDMO Dynamics
3.3 Market Dynamics
3.3.1 Market Driver Impact Analysis
3.3.1.1 High Potential Of Live Biotherapeutic Products And Microbiome In Treating Chronic & Infectious Diseases
3.3.1.2 Increase In Clinical Research On Live Biotherapeutic Products
3.3.1.3 Increasing Demand For One-Stop-Shop CDMOs
3.3.2 Market Restraint Analysis
3.3.2.1 Compliance Issues In Outsourcing
3.3.2.2 Availability Of Substitutes
3.4 Live Biotherapeutic Products and Microbiome CDMO Market: Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 Pestel Analysis
3.5 Live Biotherapeutic Products And Microbiome CDMO Market, By Application Type
3.5.1 Global Live Biotherapeutic Products And Microbiome CDMO Market, By Type, 2023 (Percent Share %)
3.6 Impact Of Covid-19 On Live Biotherapeutic Products And Microbiome CDMO Market
3.6.1 Disrupted Clinical Trials
3.7 Post COVID-19 Market Scenario
CHAPTER 4 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: APPLICATION ANALYSIS
4.1 Live Biotherapeutic Products and Microbiome CDMO Market by Application Segment: Key Takeaways
4.2 Live Biotherapeutic Products and Microbiome CDMO Market: Application Movement Analysis
4.3 Live Biotherapeutic Products and Microbiome CDMO Market Estimates & Forecast by Application (USD Million)
4.4 C. difficile
4.4.1 C. Difficile Market, 2018 - 2030 (USD Million)
4.5 Crohn's disease
4.5.1 CROHN'S Disease Market, 2018 - 2030 (USD Million)
4.6 IBS
4.6.1 IBS Market, 2018 - 2030 (USD Million)
4.7 Diabetes
4.7.1 Diabetes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: REGIONAL ANALYSIS
5.1 Live Biotherapeutic Products and Microbiome CDMO: Market Share Analysis, 2023 & 2030
5.2 Live Biotherapeutic Products and Microbiome CDMO: Market Estimates and Forecast, by Region (USD Million)
5.3 North America
5.3.1 Competitive Scenario
5.3.2 Regulatory Scenario
5.3.3 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.4 U.S.
5.3.4.1 Key Country Dynamics
5.3.4.2 Competitive Scenario
5.3.4.3 U.S. Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.5 Canada
5.3.5.1 Key Country Dynamics
5.3.5.2 Competitive Scenario
5.3.5.3 Canada Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4 Europe
5.4.1 Competitive Scenario
5.4.2 Regulatory Scenario
5.4.3 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.4 UK
5.4.4.1 Key Country Dynamics
5.4.4.2 Competitive Scenario
5.4.4.3 UK Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.5 Germany
5.4.5.1 Key Country Dynamics
5.4.5.2 Competitive Scenario
5.4.5.3 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.6 France
5.4.6.1 Key Country Dynamics
5.4.6.2 Competitive Scenario
5.4.6.3 France Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.7 Italy
5.4.7.1 Key Country Dynamics
5.4.7.2 Competitive Scenario
5.4.7.3 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.8 Spain
5.4.8.1 Key Country Dynamics
5.4.8.2 Competitive Scenario
5.4.8.3 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.9 Denmark
5.4.9.1 Key Country Dynamics
5.4.9.2 Competitive Scenario
5.4.9.3 Denmark Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.10 Sweden
5.4.10.1 Key Country Dynamics
5.4.10.2 Competitive Scenario
5.4.10.3 Sweden Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.11 Norway
5.4.11.1 Key Country Dynamics
5.4.11.2 Competitive Scenario
5.4.11.3 Norway Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5 Asia Pacific
5.5.1 Competitive Scenario
5.5.2 Regulatory Scenario
5.5.3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.5.4 China
5.5.4.1 Key Country Dynamics
5.5.4.2 Competitive Scenario
5.5.4.3 China Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.5 Japan
5.5.5.1 Key Country Dynamics
5.5.5.2 Competitive Scenario
5.5.5.3 Japan Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.6 India
5.5.6.1 Key Country Dynamics
5.5.6.2 Competitive Scenario
5.5.6.3 India Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.7 Australia
5.5.7.1 Key Country Dynamics
5.5.7.2 Competitive Scenario
5.5.7.3 Australia Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.8 Thailand
5.5.8.1 Key Country Dynamics
5.5.8.2 Competitive Scenario
5.5.8.3 Thailand Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.9 South Korea
5.5.9.1 Key Country Dynamics
5.5.9.2 Competitive Scenario
5.5.9.3 South Korea Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6 Latin America
5.6.1 Competitive Scenario
5.6.2 Regulatory Scenario
5.6.3 Latin America Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.4 Brazil
5.6.4.1 Key Country Dynamics
5.6.4.2 Competitive Scenario
5.6.4.3 Brazil Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.5 Mexico
5.6.5.1 Key Country Dynamics
5.6.5.2 Competitive Scenario
5.6.5.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.6 Argentina
5.6.6.1 Key Country Dynamics
5.6.6.2 Competitive Scenario
5.6.6.3 Argentina Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7 MEA
5.7.1 Competitive Scenario
5.7.2 Regulatory Scenario
5.7.3 MEA Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.4 South Africa
5.7.4.1 Key Country Dynamics
5.7.4.2 Competitive Scenario
5.7.4.3 South Africa Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.5 Saudi Arabia
5.7.5.1 Key Country Dynamics
5.7.5.2 Competitive Scenario
5.7.5.3 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.6 UAE
5.7.6.1 Key Country Dynamics
5.7.6.2 Competitive Scenario
5.7.6.3 UAE Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.7 Kuwait
5.7.7.1 Key Country Dynamics
5.7.7.2 Competitive Scenario
5.7.7.3 Kuwait Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 6 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: COMPETITIVE LANDSCAPE
6.1. Market Participant Categorization
6.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
6.3. Company Profiles
6.3.1. Strategy Mapping
6.3.2. Service Launches
6.3.3. Acquisition
6.3.4. Partnerships/Agreements/Collaboration
6.3.5. Expansions
6.4. Vendor Landscape
6.4.1. Key company market share analysis, 2023
6.4.2. Arrant Bio
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Service benchmarking
6.4.2.4. Strategic initiatives
6.4.3. 4D Pharma
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Service benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Cerbios
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Service benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Biose Industrie
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Service benchmarking
6.4.5.4. Strategic initiatives
6.4.6. Assembly Biosciences, Inc
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Service benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Wacker Chemie AG
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Service benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Quay Pharmaceuticals
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Service benchmarking
6.4.8.4. Strategic initiatives
6.4.9. NIZO
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Service benchmarking
6.4.9.4. Strategic initiatives
6.4.10. LONZA
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Service benchmarking
6.4.10.4. Strategic initiatives
6.4.11. Inpac Probiotics
6.4.11.1. Company overview
6.4.11.2. Financial performance
6.4.11.3. Service benchmarking
6.4.11.4. Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Live Biotherapeutic Products And Microbiome CDMO Market: Cagr Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
CHAPTER 3 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Live Biotherapeutic Products And Microbiome CDMO Dynamics
3.3 Market Dynamics
3.3.1 Market Driver Impact Analysis
3.3.1.1 High Potential Of Live Biotherapeutic Products And Microbiome In Treating Chronic & Infectious Diseases
3.3.1.2 Increase In Clinical Research On Live Biotherapeutic Products
3.3.1.3 Increasing Demand For One-Stop-Shop CDMOs
3.3.2 Market Restraint Analysis
3.3.2.1 Compliance Issues In Outsourcing
3.3.2.2 Availability Of Substitutes
3.4 Live Biotherapeutic Products and Microbiome CDMO Market: Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 Pestel Analysis
3.5 Live Biotherapeutic Products And Microbiome CDMO Market, By Application Type
3.5.1 Global Live Biotherapeutic Products And Microbiome CDMO Market, By Type, 2023 (Percent Share %)
3.6 Impact Of Covid-19 On Live Biotherapeutic Products And Microbiome CDMO Market
3.6.1 Disrupted Clinical Trials
3.7 Post COVID-19 Market Scenario
CHAPTER 4 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: APPLICATION ANALYSIS
4.1 Live Biotherapeutic Products and Microbiome CDMO Market by Application Segment: Key Takeaways
4.2 Live Biotherapeutic Products and Microbiome CDMO Market: Application Movement Analysis
4.3 Live Biotherapeutic Products and Microbiome CDMO Market Estimates & Forecast by Application (USD Million)
4.4 C. difficile
4.4.1 C. Difficile Market, 2018 - 2030 (USD Million)
4.5 Crohn's disease
4.5.1 CROHN'S Disease Market, 2018 - 2030 (USD Million)
4.6 IBS
4.6.1 IBS Market, 2018 - 2030 (USD Million)
4.7 Diabetes
4.7.1 Diabetes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)
CHAPTER 5 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: REGIONAL ANALYSIS
5.1 Live Biotherapeutic Products and Microbiome CDMO: Market Share Analysis, 2023 & 2030
5.2 Live Biotherapeutic Products and Microbiome CDMO: Market Estimates and Forecast, by Region (USD Million)
5.3 North America
5.3.1 Competitive Scenario
5.3.2 Regulatory Scenario
5.3.3 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.4 U.S.
5.3.4.1 Key Country Dynamics
5.3.4.2 Competitive Scenario
5.3.4.3 U.S. Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.5 Canada
5.3.5.1 Key Country Dynamics
5.3.5.2 Competitive Scenario
5.3.5.3 Canada Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4 Europe
5.4.1 Competitive Scenario
5.4.2 Regulatory Scenario
5.4.3 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.4 UK
5.4.4.1 Key Country Dynamics
5.4.4.2 Competitive Scenario
5.4.4.3 UK Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.5 Germany
5.4.5.1 Key Country Dynamics
5.4.5.2 Competitive Scenario
5.4.5.3 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.6 France
5.4.6.1 Key Country Dynamics
5.4.6.2 Competitive Scenario
5.4.6.3 France Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.7 Italy
5.4.7.1 Key Country Dynamics
5.4.7.2 Competitive Scenario
5.4.7.3 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.8 Spain
5.4.8.1 Key Country Dynamics
5.4.8.2 Competitive Scenario
5.4.8.3 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.9 Denmark
5.4.9.1 Key Country Dynamics
5.4.9.2 Competitive Scenario
5.4.9.3 Denmark Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.10 Sweden
5.4.10.1 Key Country Dynamics
5.4.10.2 Competitive Scenario
5.4.10.3 Sweden Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.11 Norway
5.4.11.1 Key Country Dynamics
5.4.11.2 Competitive Scenario
5.4.11.3 Norway Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5 Asia Pacific
5.5.1 Competitive Scenario
5.5.2 Regulatory Scenario
5.5.3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.5.4 China
5.5.4.1 Key Country Dynamics
5.5.4.2 Competitive Scenario
5.5.4.3 China Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.5 Japan
5.5.5.1 Key Country Dynamics
5.5.5.2 Competitive Scenario
5.5.5.3 Japan Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.6 India
5.5.6.1 Key Country Dynamics
5.5.6.2 Competitive Scenario
5.5.6.3 India Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.7 Australia
5.5.7.1 Key Country Dynamics
5.5.7.2 Competitive Scenario
5.5.7.3 Australia Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.8 Thailand
5.5.8.1 Key Country Dynamics
5.5.8.2 Competitive Scenario
5.5.8.3 Thailand Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.9 South Korea
5.5.9.1 Key Country Dynamics
5.5.9.2 Competitive Scenario
5.5.9.3 South Korea Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6 Latin America
5.6.1 Competitive Scenario
5.6.2 Regulatory Scenario
5.6.3 Latin America Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.4 Brazil
5.6.4.1 Key Country Dynamics
5.6.4.2 Competitive Scenario
5.6.4.3 Brazil Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.5 Mexico
5.6.5.1 Key Country Dynamics
5.6.5.2 Competitive Scenario
5.6.5.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.6 Argentina
5.6.6.1 Key Country Dynamics
5.6.6.2 Competitive Scenario
5.6.6.3 Argentina Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7 MEA
5.7.1 Competitive Scenario
5.7.2 Regulatory Scenario
5.7.3 MEA Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.4 South Africa
5.7.4.1 Key Country Dynamics
5.7.4.2 Competitive Scenario
5.7.4.3 South Africa Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.5 Saudi Arabia
5.7.5.1 Key Country Dynamics
5.7.5.2 Competitive Scenario
5.7.5.3 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.6 UAE
5.7.6.1 Key Country Dynamics
5.7.6.2 Competitive Scenario
5.7.6.3 UAE Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.7 Kuwait
5.7.7.1 Key Country Dynamics
5.7.7.2 Competitive Scenario
5.7.7.3 Kuwait Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
CHAPTER 6 LIVE BIOTHERAPEUTIC PRODUCTS AND MICROBIOME CDMO MARKET: COMPETITIVE LANDSCAPE
6.1. Market Participant Categorization
6.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
6.3. Company Profiles
6.3.1. Strategy Mapping
6.3.2. Service Launches
6.3.3. Acquisition
6.3.4. Partnerships/Agreements/Collaboration
6.3.5. Expansions
6.4. Vendor Landscape
6.4.1. Key company market share analysis, 2023
6.4.2. Arrant Bio
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Service benchmarking
6.4.2.4. Strategic initiatives
6.4.3. 4D Pharma
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Service benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Cerbios
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Service benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Biose Industrie
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Service benchmarking
6.4.5.4. Strategic initiatives
6.4.6. Assembly Biosciences, Inc
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Service benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Wacker Chemie AG
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Service benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Quay Pharmaceuticals
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Service benchmarking
6.4.8.4. Strategic initiatives
6.4.9. NIZO
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Service benchmarking
6.4.9.4. Strategic initiatives
6.4.10. LONZA
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Service benchmarking
6.4.10.4. Strategic initiatives
6.4.11. Inpac Probiotics
6.4.11.1. Company overview
6.4.11.2. Financial performance
6.4.11.3. Service benchmarking
6.4.11.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 4 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 5 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 6 Europe live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 7 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 8 UK live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 9 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 10 France live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 11 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 12 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 13 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 15 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 16 Asia Pacific live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 17 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 18 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 China live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 20 India live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 21 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 22 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 23 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Latin America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 25 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 26 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 27 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 28 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 29 MEA live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 30 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 31 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 33 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 34 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 4 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 5 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 6 Europe live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 7 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 8 UK live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 9 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 10 France live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 11 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 12 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 13 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 15 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 16 Asia Pacific live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 17 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 18 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 China live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 20 India live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 21 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 22 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 23 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Latin America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 25 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 26 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 27 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 28 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 29 MEA live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 30 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 31 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 33 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 34 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Live biotherapeutic products and microbiome CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data Analysis Models
Fig. 5 Market Formulation And Validation
Fig. 6 Data Validating & Publishing
Fig. 7 Commodity flow analysis
Fig. 8 Market snapshot
Fig. 9 Segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Parent market outlook, 2023 USD (Billion)
Fig. 12 Ancillary market outlook, 2023 (USD Billion)
Fig. 13 Live biotherapeutic products and microbiome CDMO market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
Fig. 16 Live biotherapeutic products and microbiome CDMO market, by type, 2023 (Revenue percent share %)
Fig. 17 Companies with affected trials, by size
Fig. 18 Affected trials, by study phase
Fig. 19 Clinical trial scenario (as of January 2022)
Fig. 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
Fig. 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
Fig. 22 C. difficile market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 IBS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2023 & 2030
Fig. 29 Regional outlook, 2023 & 2030
Fig. 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Key country dynamics
Fig. 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Key country dynamics
Fig. 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Key country dynamics
Fig. 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Market participant categorization
Fig. 82 Heat map analysis
Fig. 83 Market participant categorization
Fig. 1 Live biotherapeutic products and microbiome CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data Analysis Models
Fig. 5 Market Formulation And Validation
Fig. 6 Data Validating & Publishing
Fig. 7 Commodity flow analysis
Fig. 8 Market snapshot
Fig. 9 Segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Parent market outlook, 2023 USD (Billion)
Fig. 12 Ancillary market outlook, 2023 (USD Billion)
Fig. 13 Live biotherapeutic products and microbiome CDMO market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
Fig. 16 Live biotherapeutic products and microbiome CDMO market, by type, 2023 (Revenue percent share %)
Fig. 17 Companies with affected trials, by size
Fig. 18 Affected trials, by study phase
Fig. 19 Clinical trial scenario (as of January 2022)
Fig. 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
Fig. 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
Fig. 22 C. difficile market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 IBS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2023 & 2030
Fig. 29 Regional outlook, 2023 & 2030
Fig. 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Key country dynamics
Fig. 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Key country dynamics
Fig. 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Key country dynamics
Fig. 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Market participant categorization
Fig. 82 Heat map analysis
Fig. 83 Market participant categorization
